Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Oct 8, 2009

Premium

Title: siRNA Targeting Polo-Like Kinase-1

Number: 7,598,370

Filed: June 15, 2007

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to PLK-1."


Title: siRNA Targeting Histamine Receptor H1

Number: 7,598,369

Filed: Nov. 9, 2006

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," according to the patent's abstract. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed."


Title: Small Interfering RNAs as Non-Specific Drugs

Number: 20090246833

Filed: March 27, 2008

Lead Inventor: Joao Trindade Marques, Cleveland Clinic

The invention, the patent application's abstract states, "is directed to a method of modulating activation of a double-stranded RNA signaling pathway, such as the dsRNA signaling pathway that accompanies RNA interference of a target RNA sequence in a cell." This method, the abstract notes, comprises "introducing into the cell small interfering RNA that degrades the target RNA sequence, and maintaining the cell under conditions in which RNAi of the target RNA sequence occurs and activation of the dsRNA signaling pathway is modulated in the cell."


Title: RNAi Therapeutics for Treatment of Eye Neovascularization Diseases

Number: 20090247604

Filed: Feb. 7, 2005 PCT Filed: Feb. 7, 2005

Lead Inventor: Quinn Tang, Intradigm

The invention, the patent application's abstract states, comprises "compositions and methods for treating ocular disease. … Specifically, siRNA molecules and mixtures of siRNA molecules are provided that inhibit angiogenesis and/or neovascularization. The compositions and methods are suitable for treating ocular diseases associated with angiogenesis and/or neovascularization."


Title: RNA Interference-Mediated Inhibition of Adenosine A1 Receptor Gene Expression Using Short Interfering Nucleic Acid

Number: 20090247606

Filed: Aug. 28, 2008

Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)

The invention, the patent application's abstract states, "concerns methods and reagents useful in modulating adenosine A1 receptor gene expression in a variety of applications, including use in therapeutic, diagnostic, target-validation, and genomic-discovery applications. Specifically, the invention relates to small interfering RNA molecules capable of mediating RNA interference against ADORA1 and related receptors."


Title: dsRNA Compositions and Methods for Treating HPV Infection

Number: 20090247607

Filed: March 23, 2007 PCT Filed: March 23, 2007

Lead Inventor: John Benson, Novartis

"The invention relates to a double-stranded ribonucleic acid for treating human papillomavirus infection," the patent application's abstract states. "The dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of an HPV target gene selected from among HPV E1, HPV E6 and the human E6AP gene.

"The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by HPV infection and the expression of the E6AP gene using the pharmaceutical composition; and methods for inhibiting the expression of the HPV target genes in a cell," the abstract adds.


Title: Targeting Lipids

Number: 20090247608

Filed: Dec. 4, 2008

Lead Inventor: Muthiah Manoharan, Alnylam Pharmaceuticals

The invention "provides targeting lipids of [a defined] structure," the patent application's abstract states. "In addition, the invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo."


Title: RNA Interference-Mediated Inhibition of B Cell CLL/Lymphoma-2 Gene Expression Using Short Interfering Nucleic Acid

Number: 20090247613

Filed: Aug. 15, 2008

Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)

"This invention relates to compounds, compositions, and methods useful for modulating BCL2 gene expression using short interfering nucleic acid molecules," according to the patent application's abstract. "This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of BCL2 gene expression and/or activity by RNA interference using small nucleic acid molecules … and methods used to modulate the expression of BCL2 genes.

"The small nucleic acid molecules are useful in the treatment of cancer, malignant blood disease, polycytemia vera, idiopathic myelofibrosis, essential thrombocythemia, myelodysplastic syndromes, autoimmune disease, viral infection, and proliferative diseases and conditions," the abstract notes.


Title: Folate Conjugates

Number: 20090247614

Filed: Dec. 4, 2008

Lead Inventor: Muthiah Manoharan, Alnylam Pharmaceuticals

The invention provides an RNAi agent including at least one monomer having [a defined] structure, the patent application's abstract states.


Title: Triggered RNAi

Number: 20090247615

Filed: Feb. 27, 2009

Lead Inventor:
Niles Pierce, California Institute of Technology

The patent application, its abstract states, "relates to methods and compositions for triggering RNAi. Triggered RNAi is highly versatile because the silencing targets are independent of the detection targets. In some embodiments, methods of silencing or modulating the expression of a target gene are provided.

"The methods generally comprise providing an initiator to a cell comprising a detection target and a silencing target gene, wherein the detection target is different from the silencing target gene, [and] wherein binding of the detection target to the initiator initiates formation of an inactivator double-stranded RNA," the abstract adds. "The inactivator dsRNA can silence or modulate the expression of the silencing target gene."

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more